Accéder au contenu
Merck

Proteasome inhibition alleviates prolonged moderate compression-induced muscle pathology.

BMC musculoskeletal disorders (2011-03-10)
Parco M Siu, Bee T Teng, Xiao M Pei, Eric W Tam
RÉSUMÉ

The molecular mechanism initiating deep pressure ulcer remains to be elucidated. The present study tested the hypothesis that the ubiquitin proteasome system is involved in the signalling mechanism in pressure-induced deep tissue injury. Adult Sprague Dawley rats were subjected to an experimental compression model to induce deep tissue injury. The tibialis region of the right hind limb was subjected to 100 mmHg of static pressure for six hours on each of two consecutive days. The compression pressure was continuously monitored by a three-axial force transducer within the compression indentor. The left hind limb served as the intra-animal control. Muscle tissues underneath the compressed region were collected and used for analyses. Our results demonstrated that the activity of 20S proteasome and the protein abundance of ubiquitin and MAFbx/atrogin-1 were elevated in conjunction with pathohistological changes in the compressed muscle, as compared to control muscle. The administration of the proteasome inhibitor MG132 was found to be effective in ameliorating the development of pathological histology in compressed muscle. Furthermore, 20S proteasome activity and protein content of ubiquitin and MAFbx/atrogin-1 showed no apparent increase in the MG132-treated muscle following compression. Our data suggest that the ubiquitin proteasome system may play a role in the pathogenesis of pressure-induced deep tissue injury.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Kit de détection in situ de la mort cellulaire, fluorescéine, sufficient for ≤50 tests, suitable for detection
Sigma-Aldrich
Solution de formol, tamponnée à pH neutre (10 %), case of 48 × 15 mL, histological tissue fixative